Neogenomics Inc
Change company Symbol lookup
Select an option...
NEO Neogenomics Inc
GS Goldman Sachs Group Inc
ONON On Holding AG
XNCR Xencor Inc
ALT Altimmune Inc
RZLT Rezolute Inc
BNKU MicroSectors? U.S. Big Banks Index 3X Leveraged ETNs
SGFY Signify Health Inc
FRC First Republic Bank
BACK IMAC Holdings Inc
Go

Health Care : Health Care Providers & Services | Small Cap Blend
Company profile

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories. The Company operates through two segments: the Clinical Services Segment and the Pharma Services Segment. The Clinical Services segment provides various clinical testing services to community-based pathology practices, oncology practices, hospital pathology labs, reference labs, and academic centers with reimbursement from various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment supports pharmaceutical firms in their drug development programs by providing testing services and data analytics for clinical trials and research. The Company offers testing services, which include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry (IHC) and digital imaging, molecular testing and morphologic analysis. It operates testing laboratories in United States, Europe and Asia.

Price
Delayed
$18.59
Day's Change
0.12 (0.65%)
Bid
--
Ask
--
B/A Size
--
Day's High
19.02
Day's Low
18.51
Volume
(Light)

Today's volume of 241,003 shares is on pace to be much lighter than NEO's 10-day average volume of 1,428,563 shares.

241,003

Company Profile

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories. The Company operates through two segments: the Clinical Services Segment and the Pharma Services Segment. The Clinical Services segment provides various clinical testing services to community-based pathology practices, oncology practices, hospital pathology labs, reference labs, and academic centers with reimbursement from various payers, including client direct billing, commercial insurance, Medicare and other government payers, and patients. The Pharma Services segment supports pharmaceutical firms in their drug development programs by providing testing services and data analytics for clinical trials and research. The Company offers testing services, which include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry (IHC) and digital imaging, molecular testing and morphologic analysis. It operates testing laboratories in United States, Europe and Asia.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
4.62x
Price/Book (MRQ)
2.35x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

February 2023
Current Month
5.1M
Previous Month
4.5M
Percent of Float
4.17%
Days to Cover
2.8004 Days

Share Information

NEO is in a share class of common stock
Float
122.2M
Shares Outstanding
127.5M
Institutions Holding Shares
325
88.24%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in millions.

Cash flow

Values displayed are in millions.

Company Officers

  • Lynn A. TetraultChmn.
  • Christopher SmithCEO
  • Jeffrey Scott ShermanCFO
  • Melody HarrisCorp.Exec.
  • Vishal SikriCorp.Exec.

Address

Insider Trading

During the most recent quarter, 230 shares were bought in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2023. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.